These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 1358234

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
    Levine DS, Riff DS, Pruitt R, Wruble L, Koval G, Sales D, Bell JK, Johnson LK.
    Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
    Kruis W, Schreiber S, Theuer D, Brandes JW, Schütz E, Howaldt S, Krakamp B, Hämling J, Mönnikes H, Koop I, Stolte M, Pallant D, Ewald U.
    Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
    [Abstract] [Full Text] [Related]

  • 6. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months.
    Green JR, Swan CH, Rowlinson A, Gibson JA, Brown P, Kerr GD, Swarbrick ET, Thornton P.
    Aliment Pharmacol Ther; 1992 Oct; 6(5):647-52. PubMed ID: 1420754
    [Abstract] [Full Text] [Related]

  • 7. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group.
    Green JR, Gibson JA, Kerr GD, Swarbrick ET, Lobo AJ, Holdsworth CD, Crowe JP, Schofield KJ, Taylor MD.
    Aliment Pharmacol Ther; 1998 Dec; 12(12):1207-16. PubMed ID: 9882028
    [Abstract] [Full Text] [Related]

  • 8. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
    Muijsers RB, Goa KL.
    Drugs; 2002 Dec; 62(11):1689-705. PubMed ID: 12109930
    [Abstract] [Full Text] [Related]

  • 9. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
    Pruitt R, Hanson J, Safdi M, Wruble L, Hardi R, Johanson J, Koval G, Riff D, Winston B, Cross A, Doty P, Johnson LK.
    Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193
    [Abstract] [Full Text] [Related]

  • 10. Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational study.
    Green JR, Swan CH, Gibson JA, Kerr GD, Swarbrick ET, Thornton PC.
    Aliment Pharmacol Ther; 2004 Feb 15; 19(4):435-42. PubMed ID: 14871283
    [Abstract] [Full Text] [Related]

  • 11. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group.
    Green JR, Lobo AJ, Holdsworth CD, Leicester RJ, Gibson JA, Kerr GD, Hodgson HJ, Parkins KJ, Taylor MD.
    Gastroenterology; 1998 Jan 15; 114(1):15-22. PubMed ID: 9428213
    [Abstract] [Full Text] [Related]

  • 12. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.
    Loftus EV, Kane SV, Bjorkman D.
    Aliment Pharmacol Ther; 2004 Jan 15; 19(2):179-89. PubMed ID: 14723609
    [Abstract] [Full Text] [Related]

  • 13. Balsalazide.
    Prakash A, Spencer CM.
    Drugs; 1998 Jul 15; 56(1):83-9; discussion 90. PubMed ID: 9664201
    [Abstract] [Full Text] [Related]

  • 14. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG, Macdonald JK.
    Cochrane Database Syst Rev; 2012 Oct 17; 10():CD000543. PubMed ID: 23076889
    [Abstract] [Full Text] [Related]

  • 15. Review article: balsalazide therapy in ulcerative colitis.
    Ragunath K, Williams JG.
    Aliment Pharmacol Ther; 2001 Oct 17; 15(10):1549-54. PubMed ID: 11563993
    [Abstract] [Full Text] [Related]

  • 16. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
    Baker DE, Kane S.
    Rev Gastroenterol Disord; 2004 Oct 17; 4(2):86-91. PubMed ID: 15185719
    [Abstract] [Full Text] [Related]

  • 17. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
    Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J, Safdi M.
    Am J Gastroenterol; 1993 Aug 17; 88(8):1188-97. PubMed ID: 8338086
    [Abstract] [Full Text] [Related]

  • 18. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
    Sandborn WJ.
    Rev Gastroenterol Disord; 2006 Aug 17; 6(2):97-105. PubMed ID: 16699478
    [Abstract] [Full Text] [Related]

  • 19. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine.
    McIntyre PB, Rodrigues CA, Lennard-Jones JE, Barrison IG, Walker JG, Baron JH, Thornton PC.
    Aliment Pharmacol Ther; 1988 Jun 17; 2(3):237-43. PubMed ID: 2908755
    [Abstract] [Full Text] [Related]

  • 20. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis.
    Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA.
    Gastroenterology; 1988 Jun 17; 94(6):1383-9. PubMed ID: 2896139
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.